| SDC2 (syndecan‑2) is a type I transmembrane heparan sulfate proteoglycan of the syndecan family that decorates its extracellular core protein with heparan sulfate chains and functions as a multifunctional cell-surface co-receptor integrating extracellular matrix, growth factor, and morphogen signals with cytoskeletal organization and intracellular kinase pathways. The protein comprises a short N‑terminal signal peptide, a luminal extracellular domain bearing heparan sulfate attachment sites, a single transmembrane segment, and a cytoplasmic tail with conserved C1 and C2 motifs and a variable region that binds PDZ-domain scaffolds and signaling adaptors; this modular structure allows SDC2 to cluster in membrane microdomains and assemble signaling complexes at sites of cell–matrix and cell–cell contact. Heparan sulfate chains on SDC2 bind a range of ligands including fibronectin, thrombospondin, FGF2, EGF-family ligands, and other ECM and growth factors, and these interactions facilitate ligand presentation to receptor tyrosine kinases and integrins, modulate ligand gradients, and promote integrin activation, PI3K–Akt and Ras–Raf–MEK–ERK signaling, and reorganization of the actin cytoskeleton that together support cell proliferation, adhesion, and directional migration. In neuronal tissue, SDC2 is enriched postsynaptically and regulates dendritic spine and arbor morphogenesis; postsynaptic SDC2 recruits and organizes FGF22-dependent transsynaptic signaling that coordinates presynaptic and postsynaptic assembly, illustrating how SDC2 functions as a synaptic organizer that couples heparan sulfate–mediated ligand binding with local cytoskeletal and receptor rearrangements. During development and epithelial morphogenesis, SDC2 participates in FGF2- and FGF receptor–dependent signaling in specialized epithelia, and in multiple systems it influences branching morphogenesis, angiogenesis, and tissue patterning by regulating local availability and receptor engagement of growth factors and by modulating downstream ERK and PI3K pathways. In colorectal cancer, SDC2 expression is significantly upregulated and the protein promotes proliferation, migration, invasion, and epithelial–mesenchymal transition, with SDC2 knockdown reducing p‑MEK/MEK and p‑ERK/ERK ratios and reversing EMT marker changes, which indicates that SDC2 amplifies MAPK signaling and EMT programs to support tumor progression. Additional work shows that SDC2 contributes to 5‑fluorouracil resistance in colorectal cancer by acting downstream of miR‑20b‑5p and engaging the JNK/ERK signaling pathway; SDC2 overexpression increases survival of 5‑FU–treated cells, whereas SDC2 suppression restores drug sensitivity, defining a miR‑20b‑5p/SDC2–JNK/ERK axis that links SDC2 expression to chemoresistance. SDC2 is also enriched in cancer-derived extracellular vesicles and co‑packages with fibronectin and other cargo, supporting roles in vesicle biogenesis and intercellular communication that propagate pro-metastatic signals in the tumor microenvironment. SDC2 expression in the nervous system and other tissues ties it to dendritic and synaptic development, wound healing, angiogenesis, and immune signaling, and SDC2 gene methylation is being exploited as a noninvasive epigenetic biomarker for early detection of colorectal neoplasia, where hypermethylated SDC2 DNA in stool or plasma reflects tumor-associated epigenetic alteration of this signaling proteoglycan. |
